Delgocitinib: A Look at Its Structure, Mechanism, and Development
Delgocitinib is a Janus kinase (JAK) inhibitor used to treat atopic dermatitis. It is an oral medication that works by targeting specific JAK enzymes in the body.
What is Delgocitinab's Chemical Structure?
Delgocitinab's chemical structure is characterized by its molecular formula C23H26N4O4S. Its systematic IUPAC name is (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)tetrahydro-2H-pyran-4-carbonitrile. [1]
How Does Delgocitinab Work?
Delgocitinab inhibits the activity of Janus kinases (JAKs), specifically JAK1, JAK2, JAK3, and TYK2. These enzymes are involved in signaling pathways that regulate immune responses and inflammation. By inhibiting JAKs, delgocitinab reduces the production of cytokines that contribute to the symptoms of atopic dermatitis, such as itching and skin inflammation. [1]
What is the Synthesis Process for Delgocitinab?
The synthesis of delgocitinab involves a multi-step process. One described route begins with the preparation of chiral epichlorohydrin derivatives. This is followed by reactions to introduce the pyrrolo[2,3-d]pyrimidine core and the tetrahydropyran ring. Key steps include the formation of a nitrile group and the introduction of the methyl and amino functionalities. The synthesis requires careful control of stereochemistry to obtain the desired enantiomer. [2]
When Does Delgocitinab's Patent Protection End?
Patent information for delgocitinab can be tracked through patent databases. For example, DrugPatentWatch.com lists patents related to delgocitinab. While specific expiry dates are subject to regional patent laws and potential challenges, understanding the patent landscape is crucial for anticipating market entry of generic or biosimilar versions. [3]
Who Are the Competitors in the JAK Inhibitor Market?
The market for JAK inhibitors includes several other drugs, such as upadacitinib (Rinvoq), abrocitinib (Cibinqo), and baricitinib (Olumiant), which are also used for inflammatory conditions. These drugs compete for market share in treating conditions like atopic dermatitis, rheumatoid arthritis, and ulcerative colitis. [4]
What is the Regulatory Status of Delgocitinab?
Delgocitinab has received marketing authorization in various regions. For instance, it is approved in Japan for the treatment of atopic dermatitis. The regulatory approval process involves rigorous review of clinical trial data to demonstrate safety and efficacy. [5]
What Clinical Data Supports Delgocitinab's Use?
Clinical trials have shown that delgocitinab is effective in reducing the signs and symptoms of moderate to severe atopic dermatitis. Studies have demonstrated significant improvements in skin clearance and reductions in itch compared to placebo. Long-term safety and efficacy data are also gathered during post-market surveillance. [5]
---
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/drug/delgocitinib
[4] https://www.drugpatentwatch.com/drug/upadacitinib
[5] https://www.drugpatentwatch.com/drug/abrocitinib